biostudies-literatureUnknown14(19)Koehler RC<h4>Background</h4>The Stroke Preclinical Assessment Network tested 6 therapeutic interventions initiated at the time of reperfusion after focal ischemic stroke in young mice, aging mice, obese mice, and spontaneously hypertensive rats. This randomized, controlled trial was conducted across 6 sites with concealed treatment and blinded neurobehavior assessments. The trial had an adaptive design with preset levels of efficacy and futility interrogated after each of 4 stages. The primary outcome was turning preference on the corner test at 1 month. The PARP (poly(ADP-ribose) polymerase) inhibitor, veliparib, was considered futile after the second stage when pooling all animal models (<i>n</i>=231 veliparib; <i>n</i>=344 placebo).<h4>Methods</h4>A secondary analysis was performed to evaluate vJournal of the American Heart Associatione040914https://www.ebi.ac.uk/biostudies/studies/S-EPMC12684482biostudies-literatureMulticenter Stroke Preclinical Assessment Network Analysis of Cardiovascular Risk Factor Subgroups Treated With the Poly(ADP-Ribose) Polymerase Inhibitor Veliparib.PMC12684482Nagarkatti KASiddiqui SBibic AHyder FWang KErdogan TDShi YThedens DMcCullough LDNagarkatti KGoh AAkhter KImai TJin XAyata CBeatty HEBedirian KAvery BDDawson TDawson VLo EKumskova MKimberly WTLamb JChauhan ADiaz-Perez SVan Leyen KSansing LHde Morais ALAronowski JImmakavar EYu LNisar MHerman ALLyden PDDhanesha NQin TAvery BObertas LDawson TMMandeville JBBoisserand LSBSanganahalli BGJohnson CChauhan AKMihailovic JMKaruppagounder SSWhittier JPWKoehler RCHess DCSPAN investigators [Link]Smith CDiniz MALannon SPatel RBVelazquez SEDawson VLLeira ECKamat PKArbab ASJaroslaw Aronowski MDDhandapani KMHuang SChen MHCao SArai KKhan MBfalseMulticenter Stroke Preclinical Assessment Network Analysis of Cardiovascular Risk Factor Subgroups Treated With the Poly(ADP-Ribose) Polymerase Inhibitor Veliparib.<h4>Background</h4>The Stroke Preclinical Assessment Network tested 6 therapeutic interventions initiated at the time of reperfusion after focal ischemic stroke in young mice, aging mice, obese mice, and spontaneously hypertensive rats. This randomized, controlled trial was conducted across 6 sites with concealed treatment and blinded neurobehavior assessments. The trial had an adaptive design with preset levels of efficacy and futility interrogated after each of 4 stages. The primary outcome was turning preference on the corner test at 1 month. The PARP (poly(ADP-ribose) polymerase) inhibitor, veliparib, was considered futile after the second stage when pooling all animal models (<i>n</i>=231 veliparib; <i>n</i>=344 placebo).<h4>Methods</h4>A secondary analysis was performed to evaluate v2025-01-01T00:00:00Z2025 Oct2026-06-06T00:04:35.277Z2026-05-23T03:13:25.434ZS-EPMC126844824099606510.1161/JAHA.124.040914